Advanced Accelerator Applications S.A. (AAAP) is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. It is engaged in developing its therapeutic candidate, Lutathera, which is a compound for the treatment of neuro endocrine tumors (NETs). It has a portfolio of approximately six diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology and neurology. Its products in clinical development include Lutathera, Somakit and Annexin V-128. Its commercial products include Gluscan/Gluscan 500/Barnascan, IASOflu, IASOdopa, DOPAVIEW, IASOcholine, AAACholine, MIBITEC/Adamibi and Leukokit.
Analyst Upgrade/Downgrade Update Brokerage firm: Wells Fargo Change: Coverage Initiated Previous Rating: N/A Current Rating: Outperform Previous Price Target: N/A Current Price Target: N/A
